Developments in mood stabilisers

British Medical Bulletin

Volumn 57, Issue , 2001, Pages 179-192

  Ferrier, I N ^a  

^a NEWCASTLE UNIVERSITY   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ANTICONVULSIVE AGENT; CARBAMAZEPINE; LAMOTRIGINE; LITHIUM; VALPROIC ACID;

ARTICLE; DEPRESSION; DRUG EFFECT; DRUG EFFICACY; DRUG USE; HUMAN; MANIC DEPRESSIVE PSYCHOSIS; PRIORITY JOURNAL; TREATMENT INDICATION;

ANTICONVULSANTS; ANTIDEPRESSIVE AGENTS; ANTIPSYCHOTIC AGENTS; BIPOLAR DISORDER; CARBAMAZEPINE; ELECTROCONVULSIVE THERAPY; ELECTROMAGNETIC FIELDS; FRUCTOSE; HUMANS; LITHIUM; NIPECOTIC ACIDS; PSYCHOTHERAPY; SUICIDE; THYROXINE; TRIAZINES; VALPROIC ACID;

EID: 0034952603     PISSN: 00071420     EISSN: None     Source Type: Journal    
DOI: 10.1093/bmb/57.1.179     Document Type: Article

References (65)

1. Manic-depressive illness
2. Psychotherapy for bipolar disorder
3. Global mortality, disability and the contribution of risk factors: Global burden of disease study
4. The epidemiology of mood disorders
5. Non-lithium treatment of bipolar disorder
6. Lithium therapy
7. Lithium use and discontinuation in a health maintenance organisation
8. Does maintenance lithium therapy prevent recurrence of mania under ordinary clinical conditions?
9. Recurrence of mania after lithium withdrawal. Implications for the use of lithium in the treatment of bipolar affective disorder
10. Reduced morbidity after gradual discontinuation of lithium treatment for bipolar I and II disorders: A replication study
11. Effectiveness of restarting lithium treatment after its discontinuation in bipolar I and bipolar II disorders
12. A review of randomized, controlled clinical trials in acute mania
13. Bipolar disorder therapeutics: Maintenance treatment
14. Mood stabilizer combinations: A review of safety and efficacy
15. Anticonvulsants
16. Newer antidepressants and the cytochrome P450 system
17. Depression during mania. Treatment response to lithium or divalproex
18. A randomised placebo-controlled 12-month trial of divalproex and lithium in the treatment of outpatients with bipolar I disorder
19. Medication status and polycystic ovary syndrome in women with bipolar disorder: A preliminary report
20. Lamotrigine compared with lithium in mania: A double-blind randomised controlled trial
21. A double-blind placebo-controlled study of lamotrigine monotherapy in out-patients with bipolar I depression
22. A placebo-controlled evaluation of lamotrigine and gabapentin monotherapy in refractory mood disorders
23. A double-blind placebo-controlled prophylaxis study of lamotrigine in rapid-cycling bipolar disorder
24. Successful re-introduction of lamotrigine after initial rash
25. Novel alternatives and supplements to lithium and anticonvulsants for bipolar affective disorder
26. New antiepileptic drugs
27. An open label study of gabapentin in the treatment of acute mania
28. Clinical experience using gabapentin adjunctively in patients with a history of mania or hypomania
29. Gabapentin treatment of mood disorders: A preliminary study
30. Combination treatment in bipolar disorder
31. Open-label adjunctive topiramate in the treatment of bipolar disorders
32. Use of topiramate, a new anti-epileptic as a mood stabilizer
33. Treatment of acute mania with topiramate
34. Topiramate monotherapy in the maintenance treatment of bipolar I disorder: Effects on mood, weight and serum lipids
35. Tiagabine and the treatment of refractory bipolar disorder
36. Adjunctive tiagabine treatment of psychiatric disorders: Three cases
37. Tiagabine appears not to be efficacious in the treatment of acute mania
38. Mechanisms of action of anticonvulsants in affective disorders: Comparison with lithium
39. Relation of serum valproate concentration to response in mania
40. Predictors of valproate response in bipolar rapid cycling
41. Should folic acid be given to women treated with valproic acid and/or carbamazepine? Folic acid and pregnancy in epilepsy
42. Monitoring pregnancy outcomes after prenatal drug exposure through prospective pregnancy registries. A pharmaceutical company commitment
43. Does rebound mania occur on stopping carbamazepine?
44. Suicide and bipolar disorder
45. The risk of suicide in patients with bipolar disorders
46. The treatment of bipolar depression
47. Mood-stabilisers reduce the risk of developing antidepressant-induced maniform states in acute treatment of bipolar I depressed patients
48. Induction of mania with selective serotonin re-uptake inhibitors and tricyclic antidepressants
49. Treatment of bipolar affective disorder. New drug treatments are emerging, but more clinical evidence is required
50. Convulsive therapy: A review of the first 55 years
51. Electroconvulsive therapy of acute manic episodes: A review of 50 years' experience
52. A comparison of chlorpromazine and ECT in treatment of schizophrenic and manic patients
53. Comparison of therapeutic modalities for mania
54. Pharmacotherapy of depression and mixed states in bipolar disorder
55. Euphoric mania and rapid transcranial magnetic stimulation
56. Transcranial magnetic stimulation in mania: A controlled study
57. Induction of a reversible state of hypomania by rapid-rate transcranial magnetic stimulation over the left prefrontal lobe
58. Acute manic symptomatology during repetitive transcranial magnetic stimulation in a patient with bipolar depression
59. Association between lower serum free T4 and greater mood instability and depression in lithium-maintained bipolar patients
60. Rapid cycling bipolar affective disorder. II. Treatment of refractory rapid cycling with high-dose levothyroxine: A preliminary study
61. Treatment of intractable rapid-cycling manic-depressive disorder with levothyroxine. Clinical observations
62. Randomised controlled trial of the efficacy of teaching patients with bipolar disorder to identify early symptoms of relapse and obtain treatment
63. Cognitive vulnerability in patients with bipolar disorder
64. Cognitive therapy for bipolar depression: A pilot study